FindTrial
Sign In

XIENCE V® Everolimus Eluting Coronary Stent

DEVICE6 trials

Sponsors

Abbott Medical Devices

Conditions

Coronary Artery DiseaseCoronary Artery RestenosisCoronary Artery StenosisCoronary DiseaseCoronary RestenosisMyocardial IschemiaStent ThrombosisStents

Phase 3

SPIRIT III Clinical Trial of the XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)
CompletedNCT00180479
Abbott Medical DevicesCoronary Artery Disease, Coronary Artery Restenosis, Coronary Artery Stenosis +5
Start: 2005-06-30End: 2011-11-30Updated: 2011-11-23
SPIRIT II: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System
CompletedNCT00180310
Abbott Medical DevicesCoronary Artery Disease, Coronary Disease, Coronary Restenosis
Start: 2005-07-31End: 2011-02-28Updated: 2011-07-20
SPIRIT IV Clinical Trial: Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System
CompletedNCT00307047
Abbott Medical DevicesCoronary Artery Disease
Start: 2006-08-31End: 2012-05-31Updated: 2012-11-07

Phase 4

SPIRIT V: Post-marketing Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in Europe
CompletedNCT00402272
Abbott Medical DevicesCoronary Artery Disease, Coronary Disease, Coronary Restenosis
Start: 2006-11-30End: 2010-06-30Updated: 2010-10-14

Unknown Phase

XIENCE V® Everolimus Eluting Coronary Stent System India Post-marketing Single-arm Study
CompletedNCT00631228
Abbott Medical DevicesCoronary Artery Disease, Coronary Disease, Coronary Restenosis
Start: 2008-06-30End: 2012-08-31Updated: 2012-08-14
XIENCE V® Everolimus Eluting Coronary Stent System USA Post-Approval Study (XIENCE V® USA-Phase 1)
CompletedNCT00676520
Abbott Medical DevicesCoronary Artery Disease
Start: 2008-07-31End: 2011-03-31Updated: 2012-11-20

Related Papers

Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents
Circulation Cardiovascular Interventions2015-05-0178 citations
1-year clinical outcomes of diabetic patients treated with everolimus-eluting bioresorbable vascular scaffolds: a pooled analysis of the ABSORB and the SPIRIT trials.
2014-04-1633 citations
Contemporary incidence and predictors of stent thrombosis and other major adverse cardiac events in the year after XIENCE V implantation: results from the 8,061-patient XIENCE V United States study.
2012-06-0162 citations
Periprocedural myocardial infarction in a randomized trial of everolimus-eluting and Paclitaxel-eluting coronary stents: frequency and impact on mortality according to historic versus universal definitions.
2012-03-2025 citations
A new era of prospective real-world safety evaluation primary report of XIENCE V USA (XIENCE V Everolimus Eluting Coronary Stent System condition-of-approval post-market study).
2011-12-0144 citations
Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus- versus paclitaxel-eluting stents pooled analysis from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials.
2011-11-01105 citations
Comparison of everolimus- and paclitaxel-eluting stents in patients with acute and stable coronary syndromes: pooled results from the SPIRIT (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (A Trial of Everolimus-Eluting Stents and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice) Trials.
2011-10-0163 citations
Outcomes in diabetic and nondiabetic patients treated with everolimus- or paclitaxel-eluting stents: results from the SPIRIT IV clinical trial (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System).
2010-12-0169 citations
Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease.
2010-05-01608 citations
Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial.
2008-04-01432 citations